FlowingFlowing
← Back to all development cases
This case was judged by an anonymized AI reviewer and has not been independently reviewed by people; inspect the draft, cards, and both outputs to assess it.
AutocompleteWith cards better28 / 280 · beu-b1e57f0bae2f4ab8

Causal inference methods for combining randomized trials and observational studies: a review

Statistics · 2011.08047v4

FLOWING EVIDENCE BENCHMARK

How do we compare writing with and without cards?

At the same writing position, the same model produces one first result with cards and one without. All 280 pairs enter the overall anonymized review, which assesses whether a decision not to continue fits the draft.

Overall: 138 with-card wins, 26 ties, 107 no-card wins, 5 pairs where neither was usable, and 4 inconclusive judgments. Both sides wrote text in 218 pairs; 48 had a deliberate stop and 14 included an invalid output.

SAME DRAFT · WITH OR WITHOUT CARDS

01 · FIXED WRITING POSITION

MANUSCRIPT

Same writing position ▌

Matched autocomplete at the same draft position

02 · TWO MATCHED VERSIONS

SHARED BY BOTH

Draft, writing task, and generation model

A · With cards

Relevant literature cards supplied

B · Without cards

No literature cards supplied

Generation model

Same model and version

A → first output

B → first output

Anonymized AI judge

First outputs are anonymized as X and Y

Continuation review: accuracy, fit to the writing task and usability
Returns: X preferred / tie / Y preferred / both unusable

Review again with the answer order swapped

HOW DOES BLIND JUDGING WORK?

① Anonymize both outputs
The AI judge sees the same draft and both first outputs without knowing which received cards.

② Compare and swap order
The judge applies task-specific criteria in X/Y and then Y/X order.

③ Review disagreements
A third pass resolves disagreements. Incomplete reviews remain in the denominator.

How are positions and cards selected?

We selected 40 writing positions in each of seven fields, for 280 comparisons. The position and relevant literature cards were set before each comparison, so both versions began from the same draft.

The main result retains every frozen position, including places where cards might not add a useful next move. This avoids selecting cases based on their outputs, but 49% describes the whole cohort, not a win rate where evidence clearly had an opportunity to help. This cohort did not record that opportunity label for each position before generation, so those two groups cannot yet be separated reliably.

CARD USE · 140/280

Reported card use in continuations with text

The model reports whether a card affected its continuation. In 140 of 280 tests it produced continuation text and reported card use. The previous count of 150 included 10 cases without continuation text and has been corrected.

COMPARISON · 70 / 7 / 30

Which written version was better?

Of the 107 reported-use cases where both versions produced text, the blinded AI judge preferred the with-card version 70 times, found 7 about the same, and preferred the without-card version 30 times.

How are the two table percentages calculated?

ADOPTION COVERAGE

140reported use with text
÷
280all positions
=
50%

WITH-CARD VERSION PREFERRED

70with cards better
÷
107comparable tests
=
65%

The percentages use different groups: 50% counts continuations with text reporting card use among all 280 tests; 65% covers the 107 such cases with text on both sides. The generating model reports card use, while an anonymized AI judge compares writing quality.

Card use is self-reported by the generator. The anonymized AI judge sees the draft and source snippets, so source-aware preference remains possible; there was no independent human review. The overall result describes these 280 frozen positions, not a win probability for any writing task.

Manuscript writing position

Text excerpt · not a PDF page

Research manuscript · excerpt

Causal inference methods for combining randomized trials and observational studies: a review

8 Conclusion

…izability and transportability of RCT from one population to another. The corresponding rich and prolific literature answers a real practical concern: external validity. Indeed, questions about external validity arise as soon as there are treatment effect heterogeneities in the populations under study. We find that, as any growing scientific field, the ideas are in flux: notations differ, implementations are scattered, and the proposed methods proposed still lack real-world benchmarks, generated hand in hand with practitioners. In addition, many open questions still remain as detailled below.

…analyses with the medical expert committee are necessary to re-define a target population of interest on which generalization is possible and medically relevant. As it is generally the case, beyond methodological and theoretical guarantees, a major step to be taken before applying a set of methods is to clearly state the causal question and estimand(s) and the associated identifiability requirements. This task is even more complex when combining data sets. A primary and fundamental concern is whether outcome, treatment, and covariates are comparable in the two studies ( Lodi et al.,, 2019 ) .

↓ Next paragraph was generated here

The highlighted text is near the writing position. This is a layout of the evaluation input, not a PDF screenshot.

A matched comparison at the same writing positionOverall AI review: With cards better

Both arms use the same model, task and manuscript context. Only the retrieved passages differ. The first recorded output from each arm is shown below.

Read overall AI review rationale

A = without cards · B = with cards

Both outputs appropriately abstain with 'complete' actions, recognizing that the visible draft already concludes with 'many open questions still remain as detailed below' — a clear transitional phrase signaling that specific open questions will follow. The draft ends with a complete thought about fundamental concerns regarding comparability of outcome, treatment, and covariates across studies, with a citation. Continuing would be redundant or speculative without knowing what specific open questions the authors intend to detail. Comparing the two: Output B is more precisely aligned with the draft's content and scholarly trajectory. The draft explicitly discusses identifiability requirements, combining data sets, and comparability concerns — all methodological/theoretical issues. Output B's focus on 'sensitivity of these methods to violations of the identifiability conditions, particularly when effect modifiers are observed in the trial but not in the target population' directly extends the draft's emphasis on identifiability and connects to the sources provided (especially the sensitivity analysis source about effect modifiers unobserved in the target population). This represents a coherent, scoped continuation of the argument about methodological challenges. Output A shifts to 'practical and regulatory obstacles to data sharing,' which introduces a new dimension (regulatory/policy issues) not signaled in the draft. While plausible as a general concern, this represents a topic drift toward implementation barriers rather than the methodological and theoretical concerns that structure the visible paragraph. The draft's focus is on causal inference methodology, not data governance. Neither output is invalid; both are usable completions. However, Output B maintains tighter thematic continuity with the draft's argument about identifiability, comparability, and methodological foundations for generalizing RCT results.

Evidence

Same model and position · retrieved passages supplied · first output

Preferred by blind review

Future work should also address the sensitivity of these methods to violations of the identifiability conditions, particularly when effect modifiers are observed in the trial but not in the target population.

Passages supplied to the Evidence version

Card 1 · Robust Estimation of the Weighted Average Treatment Effect for A Target Population

The weighted average treatment effect (WATE) is a causal measure for the comparison of interventions in a specific target population, which may be different from the population where data are sampled from. For instance, when the goal is to introduce a new treatment to a target population, the questi…

Read full passage excerpt

The weighted average treatment effect (WATE) is a causal measure for the comparison of interventions in a specific target population, which may be different from the population where data are sampled from. For instance, when the goal is to introduce a new treatment to a target population, the question is what efficacy (or effectiveness) can be gained by switching patients from a standard of care (control) to this new treatment, for which the average treatment effect for the control (ATC) estimand can be applied. In this paper, we propose two estimators based on augmented inverse probability weighting to estimate the WATE for a well defined target population (i.e., there exists a target function that describes the population of interest), using observational data. The first proposed estimator is doubly robust if the target function is known or can be correctly specified. The second proposed estimator is doubly robust if the target function has a linear dependence on the propensity score …

Card 2 · Generalizing Causal Inferences from Individuals in Randomized Trials to All Trial-Eligible Individuals

We consider methods for causal inference in randomized trials nested within cohorts of trial-eligible individuals, including those who are not randomized. We show how baseline covariate data from the entire cohort, and treatment and outcome data only from randomized individuals, can be used to ident…

Read full passage excerpt

We consider methods for causal inference in randomized trials nested within cohorts of trial-eligible individuals, including those who are not randomized. We show how baseline covariate data from the entire cohort, and treatment and outcome data only from randomized individuals, can be used to identify potential (counterfactual) outcome means and average treatment effects in the target population of all eligible individuals. We review identifiability conditions, propose estimators, and assess the estimators' finite-sample performance in simulation studies. As an illustration, we apply the estimators in a trial nested within a cohort of trial-eligible individuals to compare coronary artery bypass grafting surgery plus medical therapy vs. medical therapy alone for chronic coronary artery disease.

Card 3 · Efficient and robust methods for causally interpretable meta-analysis: transporting inferences from multiple randomized trials to a target population

We present methods for causally interpretable meta-analyses that combine information from multiple randomized trials to estimate potential (counterfactual) outcome means and average treatment effects in a target population. We consider identifiability conditions, derive implications of the condition…

Read full passage excerpt

We present methods for causally interpretable meta-analyses that combine information from multiple randomized trials to estimate potential (counterfactual) outcome means and average treatment effects in a target population. We consider identifiability conditions, derive implications of the conditions for the law of the observed data, and obtain identification results for transporting causal inferences from a collection of independent randomized trials to a new target population in which experimental data may not be available. We propose an estimator for the potential (counterfactual) outcome mean in the target population under each treatment studied in the trials. The estimator uses covariate, treatment, and outcome data from the collection of trials, but only covariate data from the target population sample. We show that it is doubly robust, in the sense that it is consistent and asymptotically normal when at least one of the models it relies on is correctly specified. We study the fi …

Card 4 · A Causal Inference Approach to Network Meta-Analysis

Abstract: While standard meta-analysis pools the results from randomized trials that compare two treatments, network meta-analysis aggregates the results of randomized trials comparing a wider variety of treatment options. However, it is unclear whether the aggregation of effect estimates across het…

Read full passage excerpt

Abstract: While standard meta-analysis pools the results from randomized trials that compare two treatments, network meta-analysis aggregates the results of randomized trials comparing a wider variety of treatment options. However, it is unclear whether the aggregation of effect estimates across heterogeneous populations will be consistent for a meaningful parameter when not all treatments are evaluated on each population. Drawing from counterfactual theory and the causal inference framework, we define the population of interest in a network meta-analysis and define the target parameter under a series of nonparametric structural assumptions. This allows us to determine the requirements for identifiability of this parameter, enabling a description of the conditions under which network meta-analysis is appropriate and when it might mislead decision making. We then adapt several modeling strategies from the causal inference literature to obtain consistent estimation of the intervention-sp …

Card 5 · Sensitivity analyses for effect modifiers not observed in the target population when generalizing treatment effects from a randomized controlled trial: Assumptions, models, effect scales, data scenarios, and implementation details

BACKGROUND: Randomized controlled trials are often used to inform policy and practice for broad populations. The average treatment effect (ATE) for a target population, however, may be different from the ATE observed in a trial if there are effect modifiers whose distribution in the target populatio…

Read full passage excerpt

BACKGROUND: Randomized controlled trials are often used to inform policy and practice for broad populations. The average treatment effect (ATE) for a target population, however, may be different from the ATE observed in a trial if there are effect modifiers whose distribution in the target population is different that from that in the trial. Methods exist to use trial data to estimate the target population ATE, provided the distributions of treatment effect modifiers are observed in both the trial and target population-an assumption that may not hold in practice. METHODS: The proposed sensitivity analyses address the situation where a treatment effect modifier is observed in the trial but not the target population. These methods are based on an outcome model or the combination of such a model and weighting adjustment for observed differences between the trial sample and target population. They accommodate several types of outcome models: linear models (including single time outcome and …

Model-reported card use

Card 5 · fact

Affected output: when effect modifiers are observed in the trial but not in the target population

Model explanation: This row supplied the concrete scenario of a treatment effect modifier observed in the trial but absent from the target population, which the conclusion names as a specific identifiability violation requiring sensitivity analysis.

No Evidence

Same model and position · no retrieved passages · first output

Not preferred in this comparison

Future work should also address the practical and regulatory obstacles to data sharing between trial sponsors and observational study holders, which currently limit the feasibility of the combined analyses reviewed here.

Earlier card-use comparison

The earlier diagnostic compared only cases with reported card use and text on both sides; its scope differs from the overall AI review above.

The blinded model review preferred the Evidence version. Its original rationale appears below.

Read the original model judgment

Output A continues the paragraph with a coherent, grounded discussion about sensitivity of methods to identifiability violations, specifically mentioning effect modifiers observed in the trial but not the target population. This directly connects to the preceding text about identifiability requirements, comparability of studies, and the Lodi et al. 2019 citation. It also aligns with Source 5 (Sensitivity analyses for effect modifiers not observed in the target population), which explicitly addresses this exact scenario. The continuation flows naturally from the 'open questions still remain as detailed below' setup. Output B introduces 'practical and regulatory obstacles to data sharing between trial sponsors and observational study holders' — a topic entirely absent from the draft and all supplied sources. None of the sources mention data sharing, regulatory obstacles, trial sponsors, or feasibility limitations of combined analyses. This is an unsupported factual claim about barriers that the draft never raises. The draft's concerns are methodological (notations differ, implementations scattered, lack of benchmarks, open questions, redefining target populations, stating causal questions, comparability of outcome/treatment/covariates), not logistical or regulatory about data sharing between entities.

The passages are input material; their presence does not mean an output used them or that they support every claim. Draft and source passages are excerpted; no simulated scores or PDF appear here.